When it comes to smoothing wrinkles and minimizing signs of aging, injectable neurotoxins remain one of the most popular options. According to the American Society of Plastic Surgeons, 7.44 million botulinum toxin type A procedures were performed in 2018, which is up 3 percent from the previous year.
Although the original neurotoxin, Allergan’s Botox, was approved in 2002, other brands and formulas followed. Dysport (Galderma) was approved in 2009, Xeomin (Merz Aesthetic) in 2010 and Jeuveau (Evolus) in 2019. While differences in molecular weight, drug medium and complexing proteins mean these brands are not interchangeable, they do all work in a similar way.

Read more at MedEsthetics >>